期刊文献+

哌拉西林/他唑巴坦优化给药方案的研究现状及临床合理应用 被引量:5

Outcomes and Rational Clinical Use of Extended or Continuous Versus Intermittent Infusion of Piperacillin/Tazobactam
原文传递
导出
摘要 目的概述哌拉西林他唑巴坦优化给药方案的研究进展,为临床合理应用提供参考。方法检索国内外发表的相关文献,比较哌拉西林/他唑巴坦采用延长输注/持续输注优化给药方案与传统的间歇输注给药方案在生物药效学和临床试验中的差异。结果优化后的给药方案能获得更高的药效学目标,临床疗效和细菌清除率至少不低于传统给药方案。结论优化后的给药方案可以作为合理使用抗菌药物的优选给药方案应用于临床。 OBJECTIVE To introduce the research progress of dosage regimen of piperacillin/tazobactam and its rational offer ref- erence for clinical use. METHODS The domestic and oversea pertinent articles were searched, analyzed and summarized, and the difference between prolonged infusion or continuous infusion and traditional infusionin pharmacodynamics and clinical trials were com- pared. RESULTS The optimized dosage regimen could achieve higher pharmacodynamics goals, with clinical efficacy and bacterial clearance not inferior to the traditional dosage regimen. CONCLUSION The prolonged or continuous infusion strategy should be rec- ommended for piperacillin/tazobactam in the clinic.
出处 《中国药学杂志》 CAS CSCD 北大核心 2016年第18期1608-1614,共7页 Chinese Pharmaceutical Journal
关键词 哌拉西林钠/他唑巴坦 延长输注/持续输注 优选给药方案 临床应用 piperzcillin/tazobactam prolonged infusion/continuous infusion ahernative dosing regimen clinical application
  • 相关文献

参考文献6

二级参考文献55

  • 1Langgartner J, Lehn N, Gltiek T, et al. Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion [J]. Chemotherapy, 2007, 53 (5) : 370-377.
  • 2Sakka SG, Glauner AK, Bulitta JB, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipencm-cilastatin in critically ill patients in a randomized, controlled trial[J]. Antimicrob Agents Chemother, 2007, 51 (9) : 3304-3310.
  • 3DeRyke CA, Kuti JL, Mansfield D, et al. Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection [J]. Am J Health Syst Pharm, 2006, 63 (8): 750-755.
  • 4Georges B, Conil JM, Cougot P, et al. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen [J]. Int J Clin Pharmacol Ther, 2005, 43 (8): 360-369.
  • 5Buck C, Bertram N, Ackermann T, et al. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion[J]. IntJ Antimicrob Agents, 2005, 25 (1): 62-67.
  • 6Roberts JA, Boots R, Rickard CM, et al. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study [J]. J Antimicrob Chemother, 2007, 59 (2): 285-291.
  • 7Lau WK, Mercer D, Itani KM, et al. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection[J]. Antimicrob Agents Chemother, 2006, 50 (11) : 3556-3561.
  • 8Rafati MR, Rouini MR, Mojtahedzadeh M, et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients [J]. Int J Antimicrob Agents, 2006, 28 (2): 122-127.
  • 9Lorente L, Lorenzo L, Mastin MM, et al. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli [J]. Ann Pharmacother, 2006, 40 (2) : 219-223.
  • 10Georges B, Conil JM, Cougot P, et al. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen [J]. Int J Clin Pharmacol Ther, 2005, 43 (8) : 360-369.

共引文献302

同被引文献44

引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部